Shao Yuxin, Yao Yi, Xiao Peng, Yang Xiaoxia, Zhang Dianlong
Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.180825.
This study aims to evaluate whether miR-22 could be used as a potential biomarker to screen breast cancer patients from healthy controls. This has never been explored.
Real time PCR analysis was carried out to explore the expression of serum miR-22 in breast cancer patients. Chi-square test was used for counting data. Log rank test was used for comparing survival curves. CoX regression model was used for univariate and multivariate prognosis analysis. In addition, we also evaluated the role of miR-22 on the migration capacity of MCF-7 cells using a wound healing assay.
We found that low expression of miR-22 was significantly associated with late TNM stage, lymph node metastasis, local recurrence, and distant metastasis. Meanwhile, low expression of miR-22 was significantly associated with short survival and poor prognosis in all patients and lymph node subgroups. Analysis of CoX univariate and multivariate models demonstrated that miR-22 is an independent prognostic marker of breast cancer. In ad-dition, overexpression of miR-22 significantly decreased the migration of MCF-7 cells, validating the tumor suppressor role of miR-22 in breast cancer cells.
In summary, low miR-22 expression may be a potential biomarker to screen breast cancer patients from healthy control.
本研究旨在评估miR-22是否可作为从健康对照中筛选乳腺癌患者的潜在生物标志物。此前从未对此进行过探索。
采用实时定量PCR分析来探究乳腺癌患者血清中miR-22的表达情况。卡方检验用于计数资料。对数秩检验用于比较生存曲线。CoX回归模型用于单因素和多因素预后分析。此外，我们还使用伤口愈合试验评估了miR-22对MCF-7细胞迁移能力的作用。
我们发现miR-22低表达与晚期TNM分期、淋巴结转移、局部复发及远处转移显著相关。同时，miR-22低表达与所有患者及淋巴结亚组患者的生存期短和预后差显著相关。CoX单因素和多因素模型分析表明，miR-22是乳腺癌的独立预后标志物。此外，miR-22过表达显著降低了MCF-7细胞的迁移能力，证实了miR-22在乳腺癌细胞中的肿瘤抑制作用。
综上所述，miR-22低表达可能是从健康对照中筛选乳腺癌患者的潜在生物标志物。
